Results 11 to 20 of about 18,762 (211)

Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern. The fragile balance between infections and autoimmunity [PDF]

open access: yes, 2020
On 7 January 2020, researchers isolated and sequenced in China from patients with severe pneumonitis a novel coronavirus, then called SARS-CoV-2, which rapidly spread worldwide, becoming a global health emergency.
Diamanti, A. P.   +4 more
core   +2 more sources

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

open access: yesRMD Open, 2023
Objectives To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy.
Josef S Smolen   +10 more
doaj   +1 more source

Real-Life Advantages and Limits of Baricitinib for the Late Treatment of Adults Hospitalized with COVID-19

open access: yesBioMed, 2023
Baricitinib, a reversible Janus-associated kinase-inhibitor, is approved for treating COVID-19, combined with Dexamethasone and, eventually, with Remdesivir (RDV).
Mariacristina Poliseno   +10 more
doaj   +1 more source

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

open access: yesArthritis Research & Therapy, 2021
Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe ...
Paul Emery   +6 more
doaj   +1 more source

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing [PDF]

open access: yes, 2020
Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing.
Brinkman, Antonia Clara Katharina   +10 more
core   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

open access: yes, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran   +2 more
core   +1 more source

EFFICACY OF BARICITINIB IN PATIENTS TREATED WITH CORTICOSTEROIDS FOR SEVERE COVID-19 PNEUMONIA: A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

open access: yesInternational Journal of Infectious Diseases, 2023
Intro: Current evidence is still lacking in use of baricitinib among COVID-19 patients that require low flow oxygen and have systemic inflammation. Therefore, we are keen to evaluate the efficacy of baricitinib therapy among this group of patients, in ...
K.H. Tay   +2 more
doaj   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

open access: yes, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu   +154 more
core   +1 more source

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update [PDF]

open access: yes, 2017
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing
Aletaha   +232 more
core   +13 more sources

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

open access: yesRMD Open, 2019
Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to ...
Désirée van der Heijde   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy